Dr Kim Branson, is SVP and Global Head, AI/ML at GSK, based in San Francisco. Kim oversees a global team of more than 50 engineers and machine learning researchers. The GSK AI/ML team is focused on the application and development of AI methodology at the intersection of functional genomics and human genetics for target discovery, causal machine learning and clinical applications. Kim joined GSK in 2019 from Genentech where he was Head of AI, Early Clinical Development. Kim received his PhD in Computational Drug Design from University of Melbourne.

Kim has been involved in large-scale machine learning and medical informatics initiatives for more than 15 years, over a range of ventures from computational drug design to disease risk prediction. Kim received degrees from the University of Adelaide, and a PhD from the University of Melbourne (Australia). He was a Peter Doherty fellow and received postdoctoral training at Stanford University. He then held leadership and consulting roles in the pharmaceutical and medical informatics industry, notably at Vertex Pharmaceuticals.

Following this, Kim worked extensively in online search as a founding member of Discovery Engine (acquired by Twitter in 2009) and in health informatics as the Founding Chief Scientist of Gliimpse (acquired by Apple in 2017), and the Founding Chief Data Scientist at Lumiata, a predictive health analytics company.